Tesamorelin is a stabilized 44-amino acid analog of human growth hormone-releasing hormone (GHRH) extensively studied in metabolic, hepatic, and neuroendocrine research. BioSim Peptides supplies Tesamorelin 20mg as a high-purity lyophilized powder for in-vitro laboratory research use only. This product is not a drug, supplement, or therapeutic agent.
What is Tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone, formally designated as a trans-3-hexenoyl-modified GHRH(1–44) peptide. The N-terminal acylation with a stabilizing fatty-acid moiety renders the peptide markedly more resistant to proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) than native GHRH, which has a circulating half-life of only minutes (Wang & Tomasi, 2009).
The molecule was developed in the late 1990s and 2000s as a long-acting growth hormone secretagogue. Published reviews describe its structural design rationale, biochemical properties, and the rationale for its use as a research tool in models of HIV-associated lipodystrophy and other conditions of altered visceral adiposity (Grunfeld, 2011; Dhillon, 2011).
In the research literature, tesamorelin is also referred to by its development code TH9507. It is closely related conceptually to other GHRH analogs and to growth hormone secretagogue receptor (GHSR) ligands such as ipamorelin and the ghrelin-mimetic class, although tesamorelin acts upstream at the GHRH receptor rather than at GHSR. This positions it as a valuable comparator peptide in laboratory studies of somatotrope physiology.
Mechanism of Action in Research Models
Tesamorelin binds to the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on anterior pituitary somatotropes. Receptor activation drives Gαs-mediated stimulation of adenylate cyclase, elevation of intracellular cyclic AMP, and ultimately pulsatile release of endogenous growth hormone (GH). The downstream consequence in preclinical and clinical research models is an increase in circulating GH and insulin-like growth factor 1 (IGF-1) (Spooner et al., 2012).
Compared to native GHRH(1–44), tesamorelin’s hexenoyl modification protects against rapid N-terminal cleavage by DPP-4 and confers extended plasma stability. This pharmacokinetic improvement has been characterized in published investigational drug reviews and enables more sustained activation of the GHRHR axis in research dosing regimens (Wang & Tomasi, 2009).
Downstream of the GH/IGF-1 axis, studies have investigated effects on lipolysis in visceral adipose tissue, hepatic lipid metabolism, and skeletal-muscle protein turnover. Transcriptomic analyses of liver tissue from tesamorelin-treated subjects in NAFLD research have demonstrated shifts in lipid-handling and fibrosis-associated gene programs (Fourman et al., 2020). These mechanistic observations underpin the use of tesamorelin as a probe of the somatotropic axis in metabolic-disease research.
An additional mechanistic consideration is that tesamorelin preserves physiologic GH pulsatility. Because the peptide acts upstream at the GHRH receptor rather than supplying exogenous GH, the somatotrope retains its native pulsatile release pattern and feedback regulation by somatostatin and IGF-1. This contrasts with direct recombinant GH administration and is a critical design feature that motivates the use of tesamorelin as a research probe in studies of pulsatile versus tonic GH exposure (Grunfeld, 2011). Published reviews describe how this property informs in-vitro and in-vivo experimental design across endocrine pharmacology laboratories.
Key Areas of Scientific Research
Visceral Adiposity and Lipodystrophy Models
Tesamorelin has been most extensively investigated in the context of HIV-associated lipodystrophy, where studies have characterized changes in visceral adipose tissue volume and waist circumference in published clinical-pharmacology trials (Dhillon, 2011; Spooner et al., 2012). For laboratory research purposes, these data inform in-vitro and ex-vivo adipocyte models exploring GHRH-axis modulation of lipid storage.
Hepatic Lipid and NAFLD Research
Investigations of nonalcoholic fatty liver disease in HIV-positive populations have used tesamorelin to probe the relationship between the GH/IGF-1 axis and hepatic steatosis. Transcriptomic profiling reported in JCI Insight identified gene-expression signatures associated with reduced hepatic fat content following tesamorelin exposure (Fourman et al., 2020).
Growth Hormone and IGF-1 Axis Studies
As a GHRH analog with improved pharmacokinetics, tesamorelin is widely used as a research tool to stimulate physiologic GH pulsatility in preclinical and translational pharmacology studies. Reviews summarize comparative effects on GH amplitude, IGF-1 induction, and feedback regulation versus native GHRH and other secretagogues (Grunfeld, 2011; O’Neal, 2010).
Cognitive and Neuroendocrine Research
The GH/IGF-1 axis has been investigated for its role in cognitive function, and tesamorelin has been used as an experimental probe of this axis in aging-research contexts (Dhillon, 2011; Spooner et al., 2012). These investigations form part of the broader basic-research interest in tesamorelin as a long-acting GHRH analog.
Comparative GH Secretagogue Pharmacology
Tesamorelin occupies a distinctive niche in the research peptide literature because it acts at the GHRH receptor, upstream of the pituitary somatotrope, whereas ghrelin-mimetic peptides such as ipamorelin and hexarelin act at GHSR-1a. Comparative pharmacology studies have used tesamorelin alongside these secretagogues to dissect feedback loops, receptor desensitization, and synergistic versus additive GH-release patterns in animal and cell-based systems (Grunfeld, 2011; Wang & Tomasi, 2009). This makes tesamorelin a benchmark reference compound for laboratories building head-to-head GH-axis assays.
Lipolysis and Adipocyte Biology
Research investigations of tesamorelin’s effects on adipose tissue have explored mechanisms downstream of GH, including hormone-sensitive lipase activation, perilipin phosphorylation, and shifts in adipocyte gene expression. Published reviews describe consistent reductions in visceral adipose tissue volume in clinical pharmacology studies, observations that motivate in-vitro work on isolated adipocytes and stromal-vascular fraction cultures (Spooner et al., 2012; Dhillon, 2011).
Musculoskeletal Research
Because of the well-described anabolic effects of the GH/IGF-1 axis on lean mass, tesamorelin has been examined in research contexts looking at skeletal-muscle protein synthesis and bone turnover. Published trial data describe modest changes in lean body mass and bone-formation markers in lipodystrophy cohorts (Grunfeld, 2011), informing translational and basic-science studies of GHRH-axis modulation of musculoskeletal physiology.
IGF-1 Pulsatility and Feedback Research
Because tesamorelin acts upstream of GH release, it has been used as a research tool to probe feedback regulation of the somatotropic axis. Published reviews summarize how tesamorelin-driven elevations in IGF-1 interact with hypothalamic somatostatin tone and GHRH neuron firing, producing characteristic patterns of pulsatile GH release that are distinct from those observed with direct GH administration (Wang & Tomasi, 2009; Grunfeld, 2011). This positions the peptide as a useful tool for laboratories investigating the systems-biology of the GH/IGF-1 axis.
Metabolic Imaging and Biomarker Research
Tesamorelin has been a focal compound in studies that combine cross-sectional imaging — including computed tomography measurement of visceral fat area and magnetic resonance proton-density fat fraction — with circulating metabolic biomarkers (Fourman et al., 2020; Dhillon, 2011). For laboratory researchers, these published datasets offer a rich substrate against which in-vitro mechanistic findings can be triangulated. Tesamorelin therefore functions both as a pharmacological probe and as an anchor compound around which broader translational research questions about visceral adiposity, hepatic fat handling, and GHRH-axis biology can be organized in laboratory experimental design.
Published Research Highlights
- Grunfeld (2011, Nature Reviews Drug Discovery) profiled tesamorelin as a stabilized GHRH analog and outlined its mechanism of action through the GHRH receptor.
- Dhillon (2011, Drugs) reviewed published clinical-pharmacology data on tesamorelin and its effects on visceral adipose tissue in HIV-associated lipodystrophy research.
- Spooner et al. (2012, Annals of Pharmacotherapy) summarized the pharmacology and reported study outcomes for tesamorelin as a growth hormone-releasing factor analog.
- Wang and Tomasi (2009, Expert Opinion on Investigational Drugs) described the chemistry and pharmacokinetics of tesamorelin, including its resistance to DPP-4 cleavage.
- Fourman et al. (2020, JCI Insight) reported transcriptomic changes in liver tissue from tesamorelin-treated subjects in an HIV-associated NAFLD cohort, defining hepatic lipid and fibrosis gene signatures.
- Dhillon (2011, BioDrugs) provided an additional spotlight review of tesamorelin in HIV-associated lipodystrophy research.
- O’Neal (2010, BETA) summarized translational pharmacology data on tesamorelin and its positioning within the GHRH-analog class.
Research Context and Comparative Notes
Tesamorelin is frequently chosen by laboratories as a reference GHRH analog in studies of the somatotropic axis because of its long-acting profile and well-documented receptor selectivity. When designing in-vitro experiments, investigators commonly include tesamorelin as a positive control for GHRH-receptor activation in primary pituitary cultures, immortalized somatotrope cell lines, and reporter systems coupled to cAMP-responsive elements. The peptide’s stability under standard buffer conditions reduces variability across replicate experiments and simplifies dose–response analyses.
For metabolic-research contexts, the published literature on tesamorelin offers a uniquely deep dataset spanning visceral adipose imaging, lipid biochemistry, hepatic transcriptomics, and IGF-1 dynamics (Fourman et al., 2020; Dhillon, 2011). This makes tesamorelin a productive starting point for cross-disciplinary investigation linking endocrine signaling with tissue-specific metabolic phenotypes in research models.
Stability, Storage, and Handling in Laboratory Settings
Tesamorelin is supplied as a lyophilized white powder. Standard peptide-handling literature recommends long-term storage of the lyophilized vial at −20 °C, protected from light and humidity. Under these conditions the peptide is generally reported to remain stable for extended periods.
For laboratory reconstitution, sterile bacteriostatic water or sterile water for injection is typically employed. Reconstituted solutions should be stored at 2–8 °C and protected from light, with use within a short window — generally a few weeks — consistent with stability profiles reported for similar GHRH analogs. Repeated freeze–thaw cycles should be avoided. Aseptic technique and appropriate biosafety practices are essential throughout. No dosing or route of administration is implied; this product is for in-vitro research use only.
Product Specifications
- Product name: Tesamorelin 20mg
- Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ (44 residues)
- Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
- Molecular weight: ~5,135.9 Da
- Purity: ≥98% by HPLC
- Presentation: Lyophilized white powder, single-use research vial
- Quantity: 20 mg per vial
- Certificate of Analysis: Included; HPLC and mass spectrometry data available on request
- Shipping: USA-based fulfillment
Why Researchers Choose BioSim Peptides
BioSim Peptides supplies research-grade Tesamorelin manufactured to a ≥98% purity specification and verified batch-by-batch by HPLC and mass spectrometry. Certificates of analysis are made available on request, providing complete chemical-identity documentation for laboratory records.
Our USA-based facility offers prompt domestic shipping with protective packaging suitable for lyophilized peptides, plus responsive customer support for questions on specifications, handling, and documentation. Laboratories investigating the GH/IGF-1 axis often pair tesamorelin with complementary research peptides such as ipamorelin or CJC-1295 to compare upstream (GHRH-receptor) and downstream (ghrelin-receptor) pathways in head-to-head in-vitro work.
References
- Grunfeld C. Tesamorelin. Nature Reviews Drug Discovery. 2011. PMID: 21283099.
- O’Neal R. Tesamorelin update. BETA. 2010. PMID: 21591600.
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID: 21668043.
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012. PMID: 22298602.
- Wang Y, Tomasi A. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009. PMID: 19243281.
- Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020. PMID: 32701508.
- Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011. PMID: 22050344.
This peptide is supplied by BioSim Peptides for in-vitro laboratory research use only. It is not a drug, supplement, cosmetic, or food product and is not intended for human or veterinary use, consumption, diagnosis, treatment, cure, or prevention of any disease. All research must comply with applicable institutional and regulatory guidelines.
Frequently Asked Questions about Tesamorelin
What is Tesamorelin?
Tesamorelin is a research peptide supplied by BioSim Peptides for in-vitro and laboratory use only. Each vial is lyophilized, lab-tested, and accompanied by a Certificate of Analysis (COA) verifying identity and purity above 98% by HPLC.
Is the Tesamorelin from BioSim Peptides third-party tested?
Yes. Every lot of Tesamorelin 20mg is independently tested by HPLC and mass spectrometry. The COA for the current batch is available on request and packaged with every order.
How should Tesamorelin be stored?
Lyophilized Tesamorelin should be stored at -20°C for long-term stability. After reconstitution with bacteriostatic water it is typically stored at 2-8°C and used within the timeframe described in the published literature for the peptide.
How fast does BioSim Peptides ship?
Orders placed before 2 PM ET ship same business day from our USA facility via tracked carriers. Most domestic orders arrive in 2-4 business days.
Is Tesamorelin approved for human use?
No. Tesamorelin is supplied for in-vitro laboratory research only. It is not a drug, dietary supplement, cosmetic, or food, and is not intended for diagnosis, treatment, cure, or prevention of any disease in humans or animals.
Reviews
There are no reviews yet.